Inspyr names Christopher Lowe president and CEO
Mr. Lowe brings to Inspyr Therapeutics more than 15 years of executive management experience in life sciences as Chief Executive Officer, Chief Financial Officer and Chief Business Officer, and has been an advisor to the Company’s Board of Directors since March 2016.
Mr. Lowe is an accomplished C-level financial and operational executive. He previously was interim CEO and CFO of publicly traded medical technology company Hansen Medical, and CFO and Chief Business Officer of publicly traded drug development company Anthera Pharmaceuticals.
Prior to that, Mr. Lowe served in various senior financial positions that included CFO of Asthmatx, a medical device company acquired by Boston Scientific, and Chief Accounting Officer and Corporate Controller of Peninsula Pharmaceuticals acquired by Johnson & Johnson.
Mr. Lowe holds a B.S. from California Polytechnic State University, San Luis Obispo and an MBA from Saint Mary’s University, Texas. He serves on the Board of Directors of privately held EpiBiome. ■
LATEST MOVES FROM Texas
- J. C. Penney elects Wonya Lucas to board
- Xplore Technologies names Robert McFarland to board
- Fossil Group appoints Jeffrey Boyer as CFO
- Houston Wire & Cable elects Roy Haley to board
- Texas Instruments elects Brian Crutcher to board
More inside POST
Jacobs and CH2M to merge in a $3.27 deal Companies